The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients - PubMed (original) (raw)
Randomized Controlled Trial
. 2007 Apr;92(4):1249-55.
doi: 10.1210/jc.2006-1882. Epub 2007 Jan 23.
Muhammad R Baig, Catherine Watson, Beth E Dunning, Monica Ligueros-Saylan, Yibin Wang, Yan-Ling He, Celia Darland, Jens J Holst, Carolyn F Deacon, Kenneth Cusi, Andrea Mari, James E Foley, Ralph A DeFronzo
Affiliations
- PMID: 17244786
- DOI: 10.1210/jc.2006-1882
Randomized Controlled Trial
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
Bogdan Balas et al. J Clin Endocrinol Metab. 2007 Apr.
Abstract
Aims/hypothesis: Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that augments meal-stimulated levels of biologically active glucagon-like peptide-1. Chronic vildagliptin treatment decreases postprandial glucose levels and reduces hemoglobin A1c in type 2 diabetic patients. However, little is known about the mechanism(s) by which vildagliptin promotes reduction in plasma glucose concentration.
Methods: Sixteen patients with type 2 diabetes (age, 48+/-3 yr; body mass index, 34.4+/-1.7 kg/m2; hemoglobin A1c, 9.0+/-0.3%) participated in a randomized, double-blind, placebo-controlled trial. On separate days patients received 100 mg vildagliptin or placebo at 1730 h followed 30 min later by a meal tolerance test (MTT) performed with double tracer technique (3-(3)H-glucose iv and 1-(14)C-glucose orally).
Results: After vildagliptin, suppression of endogenous glucose production (EGP) during 6-h MTT was greater than with placebo (1.02+/-0.06 vs. 0.74+/-0.06 mg.kg-1.min-1; P=0.004), and insulin secretion rate increased by 21% (P=0.003) despite significant reduction in mean plasma glucose (213+/-4 vs. 230+/-4 mg/dl; P=0.006). Consequently, insulin secretion rate (area under the curve) divided by plasma glucose (area under the curve) increased by 29% (P=0.01). Suppression of plasma glucagon during MTT was 5-fold greater with vildagliptin (P<0.02). The decline in EGP was positively correlated (r=0.55; P<0.03) with the decrease in fasting plasma glucose (change=-14 mg/dl).
Conclusions: During MTT, vildagliptin augments insulin secretion and inhibits glucagon release, leading to enhanced suppression of EGP. During the postprandial period, a single dose of vildagliptin reduced plasma glucose levels by enhancing suppression of EGP.
Similar articles
- Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
González-Ortiz M, Sánchez-Peña MJ, González-Ortiz LJ, Robles-Cervantes JA, García-Ortega YE, Gómez-Gaitán EA, Pérez-Rubio KG, Martínez-Abundis E. González-Ortiz M, et al. Diabetes Technol Ther. 2013 Jul;15(7):564-8. doi: 10.1089/dia.2013.0020. Epub 2013 Apr 25. Diabetes Technol Ther. 2013. PMID: 23617250 Clinical Trial. - Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Farngren J, et al. Diabetes Obes Metab. 2014 Sep;16(9):812-8. doi: 10.1111/dom.12284. Epub 2014 Mar 17. Diabetes Obes Metab. 2014. PMID: 24612221 Clinical Trial. - Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE. Azuma K, et al. J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. doi: 10.1210/jc.2007-1369. Epub 2007 Nov 27. J Clin Endocrinol Metab. 2008. PMID: 18042650 Clinical Trial. - Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
Ahrén B. Ahrén B. Expert Opin Investig Drugs. 2006 Apr;15(4):431-42. doi: 10.1517/13543784.15.4.431. Expert Opin Investig Drugs. 2006. PMID: 16548792 Review. - Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N. Mikhail N. Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845. Expert Opin Investig Drugs. 2008. PMID: 18491986 Review.
Cited by
- Advances in clinical research on glucagon.
Horie I, Abiru N. Horie I, et al. Diabetol Int. 2024 Mar 23;15(3):353-361. doi: 10.1007/s13340-024-00705-w. eCollection 2024 Jul. Diabetol Int. 2024. PMID: 39101175 Review. - DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature.
Saini K, Sharma S, Khan Y. Saini K, et al. Front Mol Biosci. 2023 May 23;10:1130625. doi: 10.3389/fmolb.2023.1130625. eCollection 2023. Front Mol Biosci. 2023. PMID: 37287751 Free PMC article. Review. - Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression.
Trzaskalski NA, Vulesevic B, Nguyen MA, Jeraj N, Fadzeyeva E, Morrow NM, Locatelli CA, Travis N, Hanson AA, Nunes JR, O'Dwyer C, van der Veen JN, Lorenzen-Schmidt I, Seymour R, Pulente SM, Clément AC, Crawley AM, Jacobs RL, Doyle MA, Cooper CL, Kim KH, Fullerton MD, Mulvihill EE. Trzaskalski NA, et al. JCI Insight. 2023 Jan 24;8(2):e154314. doi: 10.1172/jci.insight.154314. JCI Insight. 2023. PMID: 36472923 Free PMC article. - Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes.
Chong SC, Sukor N, Robert SA, Ng KF, Kamaruddin NA. Chong SC, et al. Front Endocrinol (Lausanne). 2022 Oct 4;13:1012412. doi: 10.3389/fendo.2022.1012412. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36267570 Free PMC article. - Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Qin Y, Adams J, Solis-Herrera C, Triplitt C, DeFronzo R, Cersosimo E. Qin Y, et al. Diabetes Care. 2020 Oct;43(10):2519-2527. doi: 10.2337/dc19-1993. Epub 2020 Jul 21. Diabetes Care. 2020. PMID: 32694214 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous